Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Legend Hony Acquires Stake In Guangzhou Consun Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

Legend Hony, a private investment arm of Legend Holdings, has announced that it will become a minority shareholder of Guangzhou Consun Pharmaceutical with its injection of 180 million yuan into the firm. This is Legend Hony's third foray into the pharmaceutical industry after its investment in Simcere Pharmaceutical Group and buyout of Shijiazhuang Pharmaceutical. Consun is a leading TCM drug maker for kidney diseases. Company officials disclosed that the firm intends to list in the A-share market in the near future, the probability which will be increased by Hony's partnership. The equity investor is consolidating its pharmaceutical resources to maximize its capital value. (Click here for more - Chinese language)

Table

View full table

Tags:
Latest Headlines

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

See All
UsernamePublicRestriction

Register

SC068385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By